MOR106 is the first publicly disclosed human monoclonal antibody designed to selectively target IL-17C in clinical development worldwide. MOR106 has been shown to potently inhibit the binding of IL-17C to its receptor and thus to inhibit its biological activity. Testing MOR106 in rodent inflammatory skin models of atopic dermatitis and psoriasis supports clinical development of MOR106.
MOR106 arises from a strategic discovery and co-development alliance between Galapagos and MorphoSys, in which both companies contribute their core technologies and expertise. Galapagos provides the disease-related biology including cellular assays and targets discovered using its target discovery platform. MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target and contributes full CMC development of this compound.